Generation of Directly Reprogrammed Human Endothelial Cells.

Autor:	Cho S; Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA., Xia I; Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA., Lee S; Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA., Park C; Louisiana State University Health Sciences Center, Department of Molecular & Cellular Physiology, Shreveport, LA, USA.; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea., Yoon YS; Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. yyoon5@emory.edu.; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea. yyoon5@emory.edu.
Jazyk:	angličtina
Zdroj:	Methods in molecular biology (Clifton, N.J.) [Methods Mol Biol] 2024; Vol. 2835, pp. 155-164.
DOI:	10.1007/978-1-0716-3995-5_14
Abstrakt:	Direct reprogramming provides a novel breakthrough for generating functional endothelial cells (ECs) without the need for intermediate stem or progenitor states, offering a promising resource for cardiovascular research and treatment. ETV2 is a key transcription factor that has been identified as a pioneering factor for specifying endothelial lineage. Achieving precise ETV2 induction is essential for effective endothelial reprogramming, and maintaining the reprogrammed cellular phenotype relies on a specific combination of growth factors and small molecules. Thus, we hereby provide a straightforward and comprehensive protocol for generating two distinct types of reprogrammed ECs (rECs) from human dermal fibroblasts (HDFs). Early rECs demonstrate a robust neovascularization property but lack the mature EC phenotype, while late rECs exhibit phenotypical similarity to human postnatal ECs and have a neovascularization capacity similar to early rECs. Both cell types can be derived from human somatic source cells, making them suitable for personalized disease investigations, drug discovery, and disease therapy. (© 2024. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu